Targeting liver cancer driven by FGF19 with modified FGF21
Therapeutic targeting of FGF19-driven cancers with FGF21 variants
This study is looking at new ways to treat liver cancer by understanding how a protein called FGF19 helps cancer grow and testing modified versions of another protein, FGF21, to see if they can stop that growth, which could lead to better treatment options for people with this type of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10906654 on NIH RePORTER |
What this research studies
This research focuses on developing new therapeutic options for hepatocellular carcinoma (HCC), the most common type of liver cancer, which currently has limited treatment choices. The study investigates the role of Fibroblast Growth Factor 19 (FGF19) in promoting cancer cell growth and explores how modified versions of Fibroblast Growth Factor 21 (FGF21) can inhibit this process. By enhancing the binding affinity of FGF21 variants to specific receptors, the research aims to block the cancer-promoting effects of FGF19, potentially leading to more effective treatments for patients with HCC.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with hepatocellular carcinoma who have limited treatment options.
Not a fit: Patients with liver cancer types other than hepatocellular carcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, more effective treatment option for patients suffering from liver cancer.
How similar studies have performed: Other research has shown promise in targeting similar pathways in cancer treatment, suggesting that this approach could be effective.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Lee, Sangwon — Yale University
- Study coordinator: Lee, Sangwon
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.